Shiseido cuts full year forecast

By Simon Pitman

- Last updated on GMT

Shiseido cuts full year forecast
Japanese multinational Shiseido announced steady sales and a big increase in profits for the first half of its financial years, but cuts its forecasts on the back of restructuring and currency exchange.

The company’s results for the first six months of the year showed that profits were up significant to ¥24.5bn (US$244m), compared to ¥4bn last year as positive effects from earlier restructuring filtered through.

Meanwhile the company’s revenue for the period were virtually flat compared to the previous year, registering ¥412bn, compared to ¥410bn in the same period last year.

Sales and profit forecasts down for full year

In local currency the revenue for the period was up by 5.5%, a figure that largely reflecting the negative impact of currency exchange rates on the reported figure.

However, what alarmed investors when the figures were revealed at the end of last week was the cut in forecasts for the rest of the year.  Shares fell by almost 10% upon initial reports of the forecast cut, last week.

Shiseido executives say that they expect sales for the full year 2016 to be ¥848bn, down by 2.8% from its original forecast at the beginning of the year, while the forecast for net income in 2016 was cut by 13% to ¥30bn.

In its financial statement for the half year, the company said that there had been a steady increase in its domestic Japanese business, which still accounts for around 50% of its total revenues, while other global market remained positive on the whole, despite some pockets of volatility.

Outlook contrasts first half performance

However, the company said that the outlook for the next six looks set to contrast the first half of the year, due to a growing sense of uncertainty in a number of key areas.

“This largely reflects further appreciation of the yen and a drop in stock prices, mounting anxiety toward overseas economies, and signs that corporate-sector earnings and consumer spending have stalled,”​ the company said in its financial statement.

Analysts praised the company for its second quarter performance, with a Credit Suisse report citing a noticeable improvement in the company's performance in China.

However, the same report also cautioned over the outlook, putting the reduced forecast down to internal structuring and the weakness of foreign exchange movements. 

Related news

Related products

show more

Discover Peptan for Beauty & Diverse Skins

Discover Peptan for Beauty & Diverse Skins

Content provided by Rousselot | 05-Sep-2024 | Product Brochure

As beauty from within solutions soar in popularity, manufacturers need to be able to serve everyone, no matter their ethnicity or skin type.

FucoSkin®: Ocean-Inspired Sustainable Beauty

FucoSkin®: Ocean-Inspired Sustainable Beauty

Content provided by Hi-Q Marine Biotech International Ltd | 28-Aug-2024 | White Paper

FucoSkin® is a fucoidan-rich extract derived from the brown seaweed Laminaria Japonica, known for its excellent anti-aging and photoprotective benefits....

Collagen Reimagined, Discover Biodesigned Type XXI

Collagen Reimagined, Discover Biodesigned Type XXI

Content provided by Geltor | 20-Mar-2024 | Product Brochure

Collagen is the body’s most abundant protein and a mainstream ingredient for beauty. Type XXI collagen transcends a common protein into a powerful bioactive

Empowering natural barrier function for future-proof skin

Empowering natural barrier function for future-proof skin

Content provided by Lucas Meyer Cosmetics | 14-Mar-2024 | White Paper

Corneopeptyl™ is a new patented peptide biomimetic to the LCE6A protein, obtained by green chemistry-based synthesis. By mimicking the LCE6A protein activity,...

Related suppliers

Follow us

Products

View more

Webinars

Podcast